...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European Clinical Respiratory Journal >COPD, stage and treatment in a large outpatient clinic
【24h】

COPD, stage and treatment in a large outpatient clinic

机译：大型门诊的COPD，分期和治疗

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Some COPD patients suffer from frequent exacerbations despite triple inhalation treatment. These frequent exacerbators should be identified, as exacerbations often lead to decreasing lung function and increasing mortality. Roflumilast reduces exacerbations in patients with a previous history of exacerbations. Our aim was to describe COPD patient characteristics and compare roflumilast treatment eligible to non-eligible patients. An observational cross-section study was conducted. Patients were included from a large COPD outpatient clinic. Information regarding COPD patient characteristics was registered on a standardized form and lung function was measured. Patients were categorized according to the GOLD classification. Eligibility for roflumilast treatment was assessed and patient characteristics compared between groups. 547 patients were included. Most patients (54%) were in GOLD group D. 62 patients (11.3%) met the criteria for treatment with roflumilast. Among the patients eligible for roflumilast treatment, only 14 patients (22.6%) were receiving treatment. There were no significant differences in FEV_(1), number of exacerbations, hospitalization due to exacerbation, MRC grade, age, smoking status and medication use between patients receiving roflumilast and not treated eligible patients. Our study documents low use of roflumilast treatment. In view of the established effect of roflumilast we think that this treatment should be considered more consistently as an option among COPD patients fulfilling the criteria for this therapy.
机译：尽管进行了三次吸入治疗，但一些COPD患者仍经常发作。应确定这些频繁发作的患者，因为发作常导致肺功能下降和死亡率增加。罗氟司特减少了有恶化史的患者的恶化。我们的目的是描述COPD患者的特征，并比较符合资格的罗氟司特治疗的患者。进行了观察性横断面研究。患者来自大型COPD门诊。有关COPD患者特征的信息以标准化形式注册，并测量了肺功能。根据GOLD分类对患者进行分类。评估了罗氟司特治疗的资格，并比较了两组患者的特征。包括547名患者。大多数患者（54％）属于黄金D组。62例患者（11.3％）符合罗氟司特的治疗标准。在有资格接受罗氟司特治疗的患者中，只有14名患者（22.6％）正在接受治疗。在接受罗氟司特治疗的患者和未经治疗的合格患者之间，FEV_（1），加重次数，因加重而住院，MRC等级，年龄，吸烟状况和用药之间无显着差异。我们的研究表明罗氟司特治疗的使用率低。考虑到罗氟司特的既定作用，我们认为在符合该疗法标准的COPD患者中，应更一致地将此疗法视为一种选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号